PDF
(Download)
|
- Cocoa (Theobroma cacao)
- Cardiovascular Disease Risk
- DNA Methylation
|
Date:
03-14-2014 | HC# 091311-492
|
Re: Cocoa Consumption Decreases Global DNA Methylation in Subjects with Cardiovascular Disease Risk Factors
Crescenti A, Solà R, Valls RM, et al. Cocoa consumption
alters the global DNA methylation of peripheral leukocytes in humans with cardiovascular
disease risk factors: A randomized controlled trial. PLoS One. 2013;8(6):e65744. doi: 10.1371/journal.pone.0065744.
One of the major processes associated with
epigenetics (changes in DNA expression outside of changes in the genes
themselves) is DNA methylation. It has been shown that global DNA methylation
levels in peripheral lymphocytes are associated with cardiovascular disease
(CVD) and risk factors of CVD; however, environmental and dietary factors can
modify these epigenetic effects. Polyphenolic-rich foods such as cocoa (Theobroma cacao) may prevent or alter
epigenetic changes associated with certain disease states. The aim of this
randomized, controlled study was to assess the effects that cocoa consumption
has on DNA methylation in subjects with risk factors for CVD and to determine
if gene expression of enzymes associated with DNA methylation are affected by
cocoa.
This study took place at 3 primary care centers in
3 cities across Spain (Alcover, Vic, and Centelles). There were 104
subjects in the control group (males: n=46; females: n=58) and 110 subjects in the
treatment group (males: n=45; females: n= 65). Subjects included in the study
were > 20 years of age; pre-hypertensive (systolic blood pressure [BP]:
120–139 mmHg or diastolic BP: 80–89 mmHg); stage 1 hypertensive (systolic BP:
140–159 mmHg or diastolic BP: 90–99 mmHg); with low-density lipoprotein
cholesterol (LDL-C) ≥ 130 mg/dL and ≤ 189 mg/dL; and with at least 1 other
major CVD risk factor such as age (males: > 45; females > 55 years),
smoking habit, low high-density lipoprotein cholesterol (HDL-C) (males: ≤ 40 mg/dL; females: ≤ 46 mg/dL), or a family
history of premature heart disease. Exclusion criteria were diabetes, chronic
disease, any hypolipemic treatment, body mass index (BMI) > 35 kg/m2,
or a history of CVD.
The tolerance to cocoa was first evaluated in
the treatment group for 2 weeks (6 g cocoa/d; 465 Kcal/d) while the subjects
were on an isocaloric diet (13% of energy from saturated fatty acids). The
control group also consumed an isocaloric diet during this period. They did not
consume any chocolate in the diet. After 2 weeks of treatment with the cocoa
cream product (manufacturer unknown), fasting blood samples were obtained from
the treated and untreated subjects for the isolation of peripheral leukocyte
DNA. The global methylation levels of peripheral leukocyte DNA from blood
samples and cultured peripheral blood mononuclear cells (PBMCs) were assessed
from measurements of 5-methylcytosine (5mC). Several single nucleotide
polymorphisms (SNPs) were also assessed in 3 different types of DNA
methyltransferases (DNMTs), in methylenetetrahydrofolate
reductase (MTHFR), and in methionine synthase reductase (MTRR) genes.
Additionally, PBMCs from 6 of the subjects (3 male, 3 female) were
treated with a cocoa extract (consisting mostly of proanthocyanidins [catechin,
2.374 mg/g and epicatechin, 5.638 mg/g] measured by liquid chromatography-mass
spectrometry [LC-MS]) that was similar to the cocoa product used in the human
intervention trial. The mRNA levels of DNMT, MTHFR,
and MTRR genes were analyzed from PBMCs treated with 25 mg/L and 50 mg/L of cocoa extract for 3 h
and 24 h. Global methylation was evaluated by treatment with 50 mg/L of cocoa
extract for 72 hours. Moreover, cell viability was measured in PBMCs treated
with the cocoa extract.
There were no statistical differences in
demographics or body measurements between the control and treatment groups. The
treated subjects had significantly lower %5mC in peripheral leukocyte DNA
compared to the control subjects (2.991 ± 0.366
vs. 3.909 ± 0.380; P<0.001). Gender did not
contribute to significant differences, and age did not correlate with
methylation.
It was also found that subjects with the A66G
polymorphism in the MTRR gene and men with the A1298C polymorphism in the MTHFR
gene had more global peripheral leukocyte DNA methylation in comparison with those
without polymorphisms in these genes. In addition, it was found that there was
an association between cocoa consumption and the A38946G polymorphism in DNMT3B
genes on global peripheral leukocyte DNA methylation in men.
No effects were found in methylation genes of
the PBMCs after 3 hours; however, after 24 hours of treatment at both 25 mg/L
and 50 mg/L, the mRNA expression of the DNMT1, DNMT3A, DNMT3B, MTHFR, and MTRR genes
were significantly lower compared to the control (vehicle only) cells (P≤0.05). It was also found that global DNA methylation
in the PBMCs treated with the cocoa extract (50 mg/L) had lower, although non-significant,
%5mC levels compared to the control cells (3.824 ± 0.971
vs. 4.599 ± 0.683, P=0.09).
The authors conclude that cocoa consumption decreases global DNA methylation of
peripheral leukocytes in humans with CVD risk factors. These effects were also
further validated in vitro (in PBMCs) by the inhibitory effects of cocoa
extracts on the expression of genes that play a role in DNA methylation,
suggesting a mechanism for the hypomethylation effects of cocoa. This is one of
the first studies about the epigenetic effects of cocoa consumption in human
health; further studies will help to better understand the mechanisms of the
active components of cocoa and their impact on epigenetic changes and disease
outcomes.
—Laura M. Bystrom, PhD
|